Quantitative natural history characterization in a cohort of 142 published cases of patients with galactosialidosis

• Verfasst von: Sláma, Tomáš [VerfasserIn]
• Verfasst von: Garbade, Sven [VerfasserIn]
• Verfasst von: Kölker, Stefan [VerfasserIn]
• Verfasst von: Hoffmann, Georg F. [VerfasserIn]
• Verfasst von: Ries, Markus [VerfasserIn]
• Titel: Quantitative natural history characterization in a cohort of 142 published cases of patients with galactosialidosis
• Titelzusatz: a cross-sectional study
• Verf.angabe: Tomáš Sláma, Sven F. Garbade, Stefan Kölker, Georg F. Hoffmann, Markus Ries
• Jahr: 2019
• Umfang: 8 S.
• Fussnoten: First published: 27 December 2018 ; Gesehen am 17.04.2019
• Titel Quelle: Enthalten in: Journal of inherited metabolic disease
• Ort Quelle: Hoboken, NJ : Wiley, 1978
• Jahr Quelle: 2019
• Band/Heft Quelle: 42(2019), 2, Seite 295-302
• ISSN Quelle: 1573-2665
• DOI: doi:10.1002/jimd.12010
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: drug development
• Sach-SW: galactosialidosis
• Sach-SW: orphan disease
• Sach-SW: radiological findings
• Sach-SW: survival
• K10plus-PPN: 1663394679

Abstract

Galactosialidosis (GS; OMIM #256540) is a rare multisystemic inborn glycoprotein storage disease caused by biallelic mutations in the cathepsin A gene resulting in combined deficiency of the lysosomal enzymes β-galactosidase and α-neuraminidase. The precise understanding of the natural course of the disease is limited. Development of enzyme replacement therapy is at the preclinical stage. The purpose of this research project was to quantitatively characterize the natural history of the condition. Quantitative analysis of all published cases in the literature with sufficient data (N = 142 patients) was carried out. Main outcome variables were survival, diagnostic delay, description of symptoms, biomarker-phenotype associations, and radiological findings. STROBE criteria were respected. Median survival age of the cohort was 48 years. Median age of onset was 4.25 years with interquartile range (IQR) 1 to 16 years. Median age at diagnosis was 19 (IQR: 8.92-29) years, with median diagnostic delay of 8 (IQR: 4-12) years. Patients with residual β-galactosidase activity of more than 8.6% (leukocytes) survived significantly longer than patients with lower enzyme activities.